Bloomberg Launches New Podcast Series Ending Alzheimer's

Bloomberg posted a new audio program called "Ending Alzheimer's" to its platform on Nov. 13, 2026, according to the show's listing on Bloomberg's audio site. The posting runs a nominal "0:00" in Bloomberg's own metadata, consistent with an introductory or placeholder entry rather than a full episode.

What did Bloomberg actually post?

The only confirmed data point is the title and the Nov. 13 publish date, both drawn from Bloomberg's own audio URL and listing, dated Nov. 13, 2026. Bloomberg's page does not include episode notes, a host credit, or a run-time beyond the zero-length marker, based on the material available at publication.

What does the title signal about the show's focus?

The name "Ending Alzheimer's" points to coverage of Alzheimer's disease research, treatment, or the business of fighting it, a subject area Bloomberg's audio and editorial teams have long tracked as part of health and pharmaceutical reporting. Nothing in the available listing specifies whether the series will center on drug development, patient care economics, or policy, so the editorial angle remains unconfirmed.

What details are missing from Bloomberg's announcement?

No host name, guest list, episode count, or release cadence appears in the sourced listing. Readers looking for specifics on funding sources behind any featured research, named pharmaceutical companies, or clinical-trial data will not find them in the Nov. 13 posting itself. Any of those facts would need to come from a future episode or a separate Bloomberg article once published.

How does this fit into Bloomberg's broader audio lineup?

Bloomberg distributes the show through the same audio infrastructure used for its other news podcasts, per the URL structure of the listing. That placement suggests the company is treating "Ending Alzheimer's" as a standing series rather than a one-off segment, though Bloomberg's listing does not state an explicit season order or episode schedule.

Where can listeners find it?

The program is accessible directly through Bloomberg's audio page for the series. No alternate distribution platforms, such as specific podcast-app listings, were included in the material reviewed for this report.

What to watch

• Whether Bloomberg names a host or lead correspondent once the first full episode posts.
• Whether the series centers on drug-pipeline economics, caregiving costs, or research funding.
• The release cadence Bloomberg sets, since the Nov. 13 entry carries no runtime or schedule data.
• Any tie-ins to pharmaceutical company earnings calls or FDA actions that could anchor future episodes in verifiable numbers.

HTT News will update this report once Bloomberg publishes episode-level detail, including any sourced figures on Alzheimer's treatment costs, drug trial results, or market size that meet this desk's attribution standard.

Artiglio is A coming-soon iPhone chief of staff for briefings and drafts. Not on the App Store yet.